Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
7(88%)
Results Posted
100%(1 trials)

Phase Distribution

Ph phase_2
2
25%
Ph phase_1
6
75%

Phase Distribution

6

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
6(75.0%)
Phase 2Efficacy & side effects
2(25.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

7

trials recruiting

Total Trials

8

all time

Status Distribution
Active(7)
Completed(1)

Detailed Status

Recruiting5
Active, not recruiting2
Completed1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
7
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 16 (75.0%)
Phase 22 (25.0%)

Trials by Status

completed113%
active_not_recruiting225%
recruiting563%

Recent Activity

7 active trials
Showing 5 of 8
recruitingphase_1

Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)

NCT06149481
recruitingphase_1

Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer

NCT07002320
recruitingphase_1

Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome

NCT04245397
active_not_recruitingphase_1

SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab

NCT03161431
recruitingphase_2

Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer

NCT06228053
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT06149481Phase 1

Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)

Recruiting
NCT07002320Phase 1

Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer

Recruiting
NCT04245397Phase 1

Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome

Recruiting
NCT03161431Phase 1

SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab

Active Not Recruiting
NCT06228053Phase 2

Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer

Recruiting
NCT05604560Phase 2

A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer

Active Not Recruiting
NCT04477343Phase 1

A Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Recruiting
NCT04574583Phase 1

Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta "Trap"/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT)

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8